Genentech
Coverage of Genentech in the Nexus archive.
- Bay Area biotech giant to lay off 103 employees
Genentech, a Bay Area-based biotechnology company, is laying off 103 employees from its South San Francisco headquarters. The layoffs, part of a WARN report, affect professional scientific and technical services roles.
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali Therapeutics' experimental Parkinson's drug targeting the LRRK2 protein failed to slow disease progression in a clinical trial, dealing a setback to a promising scientific approach. Separately, Genentech is offering researchers up to $125,000 in grants to produce papers on pharmaceutical pricing policies and innovation, raising questions about the independence of such research.
- STAT+: Genentech is soliciting research that can be used to blunt pharma reforms in Washington
Genentech is offering up to $125,000 in research grants to academics to generate papers on topics aligned with pharmaceutical industry talking points against drug pricing reforms, including studies on innovation impacts and R&D risks. The company is seeking 'rigorous, independent' research that could be used to influence Capitol Hill policy discussions on healthcare affordability.
- Damon Wayans reveals the scary symptom that led to his type 2 diabetes diagnosis
Comedy icon Damon Wayans revealed his type 2 diabetes diagnosis, attributing it to family history and symptoms like frequent urination, foot pain, and blurry vision. He adopted a healthier lifestyle, including diet and exercise, and now advocates for diabetes awareness through Genentech’s 'All Eye on DME' campaign to highlight vision loss risks.